Breaking News, Collaborations & Alliances

WuXi XDC, HKSTP Partner on Bioconjugate Drug Industry

HKSTP Park companies will leverage WuXi XDC's one-stop service platform to develop ADC and other bioconjugates.

WuXi XDC, a global contract, research, development, manufacturing organization (CRDMO) focused on the ADC and broader bioconjugate market, and Hong Kong Science and Technology Parks Corporation (HKSTP), entered into an agreement to jointly advance the establishment of a CRDMO value chain in Hong Kong. The partnership will drive the development of ADC and other bioconjugates in Hong Kong leveraging WuXi XDC’s services and capabilities. With the aim of boosting the biotechnology ecosystem...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters